**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 64195

**Manuscript Type:** MINIREVIEWS

**Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?**

Demirtas CO *et al*. Personalized hepatocellular carcinoma surveillance

Coskun Ozer Demirtas, Maurizia Rossana Brunetto

**Coskun Ozer Demirtas,** Department of Gastroenterology and Hepatology, Marmara University, School of Medicine, Istanbul 34854, Turkey

**Maurizia Rossana Brunetto,** Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa 56125, Italy

**Maurizia Rossana Brunetto,** Hepatology Unit, University Hospital of Pisa, Pisa 56125, Italy

**Maurizia Rossana Brunetto,** Biostructure and Bio-imaging Institute, National Research Council of Italy, Naples 56125, Italy

**Author contributions:** Demirtas CO performed the literature search and wrote the paper; Brunetto MR critically revised the manuscript; All authors approved the final version of the manuscript.

**Corresponding author: Coskun Ozer Demirtas, MD, Postdoctoral Fellow,** Department of Gastroenterology and Hepatology, Marmara University, School of Medicine, Marmara Üniversitesi Göztepe Yerleşkesi, Istanbul 34854, Turkey. coskun\_demirtas10@hotmail.com

**Received:** February 11, 2021

**Revised:** April 28, 2021

**Accepted:** August 2, 2021

**Published online:**

**Abstract**

Surveillance with abdominal ultrasound with or without alpha-fetoprotein is recommended by clinical practice guidelines for patients who are considered to be at risk of developing hepatocellular carcinoma (HCC), including those with cirrhosis, advanced fibrosis and special subgroups of chronic hepatitis B (CHB). Application of the standard surveillance strategy to all patients with chronic liver disease (CLD) with or without cirrhosis imposes major sustainability and economic burdens on healthcare systems. Thus, a number of HCC risk scores were constructed, mainly from Asian cohorts, to stratify the HCC prediction in patients with CHB. Similarly, even if less than for CHB, a few scoring systems were developed for chronic hepatitis C patients or cirrhotic patients with CLD of different etiologies. Recently, a few newsworthy HCC-risk algorithms were developed for patients with cirrhosis using the combination of serologic HCC markers and clinical parameters. Overall, the HCC risk stratification appears at hand by several validated multiple score systems, but their optimal performance is obtained only in populations who show highly homogenous clinic-pathologic, epidemiologic, etiologic and therapeutic characteristics and this limitation poses a major drawback to their sustainable use in clinical practice. A better understanding of the dynamic process driving the progression from CLD to HCC derived from studies based on molecular approaches and genetics, epigenetics and liquid biopsy will enable the identification of new biomarkers to define the individual risk of HCC in the near future, with the possibility to achieve a real and cost/effective personalization of surveillance.

**Key Words:** Hepatocellular carcinoma; Surveillance; Chronic viral hepatitis; Risk score; Risk-stratification; Hepatitis B virus; Hepatitis C virus

Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? *World J Gastroenterol* 2021; In press

**Core Tip:** The risk of hepatocellular carcinoma (HCC) is not uniform and may increase due to underlying parameters in chronic viral hepatitis. Several clinical HCC risk scores and biomarker integrated algorithms have been proposed to stratify patients according to their HCC risk level. In the present review, we summarize the efforts for personalized HCC surveillance in the literature and discuss their applicability to clinical practice.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths globally[1]. The majority of HCC cases (> 90%), at least in the Western countries, occur in the setting of cirrhosis, as approximately one-third of patients with cirrhosis eventually develop HCC in the long term, with an annual risk of 1%-8%, varying upon several risk factors[2,3]. Globally, approximately 80% of HCC are associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and their geographical distribution depends on the epidemiology of the two viral infections. Most HCCs are associated with chronic hepatitis B (CHB) virus infection (> 60%) in Asian countries, whereas chronic hepatitis C (CHC) appears to be the most commonly established etiology for HCC in western countries[4]. However, in recent years, a progressive increase of HCC in patients with non-viral (mainly metabolic) liver disease has been reported[5].

CHB has carcinogenetic potential itself by several insertional mutagenetic routes, and up to 30% of CHB-related HCCs arise in non-cirrhotic liver, mainly in Asian patients[6]. Current management of CHB with long-term nucleotide analogues treatment by inhibiting HBV replication had been shown to decrease HCC incidence. Nevertheless, despite on-therapy virological remission, the annual incidence of HCC ranges from 0.01% to 5.4% in CHB[7]. In the last decade, wondrous new achievements occurred in the treatment of CHC, and sustained virological response (SVR) rates exceeded 95% with direct-acting antiviral (DAA) therapies[8]. Successful DAA treatment has resulted in a 71% reduction in HCC risk[9]. The HCC incidence fell from 3.6% to 1.8% per year with the DAA therapies[10]. However, many patients, after the clearance of HCV infection, maintain additional co-factors of liver disease (*i.e*. metabolic or alcohol-induced liver damage) that may contribute to the persistence of a significant HCC risk. Accordingly, a recent long-term study conducted in the Veterans cohort showed that HCC incidence remained stable at 1.5 to 2.3/100 person years, even up to 3.6 years, after DAA-induced SVR[11]. Cirrhosis is the primary risk factor for HCC regardless of liver disease etiology, with an annual HCC incidence greater than 1%[12]. CHC patients with cirrhosis and advanced fibrosis (F3) continue to have a significantly elevated risk of HCC despite achieving SVR and have stayed the target of surveillance programs. According to the general principles of surveillance, the definition of the target population must consider the incidence of HCC in a specific set of patients and the probability that effective therapies, particularly the curative ones, can be applied to these patients. Decision analysis and cost-effectiveness models suggest that an intervention is considered cost-effective if it provides life expectancy increases of at least 3 mo with a cost below the threshold of ultrasonography (US) of $50000 per year of lives saved[13]. Based on these premises, there is currently a general consensus on using abdominal US with or without alpha-fetoprotein (AFP) as a diagnostic tool to perform HCC surveillance.

Beyond the fact that several host-related (cirrhosis, chronic hepatic necroinflammation, older age, male sex, African origin, alcohol abuse, chronic co-infections with other hepatitis viruses or human immunodeficiency virus, diabetes or metabolic syndrome, active smoking, positive family history) and virus-related (high HBV-DNA and/or hepatitis B surface antigen [HBsAg] levels, HBV genotype C > B, specific mutations) factors influence the risk of HCC development[14], in the setting of CHB, HCC surveillance is recommended by American Association for the Study of Liver Diseases (AASLD), Asia-Pacific Association for the Study of Liver Diseases and European Association for the Study of Liver Diseases (EASL) for all patients with cirrhosis, hepatitis B carriers with a family history of HCC, Asian males older than 40 years, Asian females older than 50 years, and African males older than 20 years[15-18]. Additionally, all patients with chronic liver disease (CLD) and advanced fibrosis (F3) are also recommended to undergo HCC surveillance by EASL[18] (Table 1). In general, a cut-off for HCC incidence of 0.2%/year for hepatitis B, 1.5%/year for hepatitis C and all cirrhotics regardless of etiology is considered cost-effective for HCC surveillance, since it was first described in AASLD guidelines in 2005[19]. However, an area of uncertainty exists for CHC patients with viral clearance but F3 fibrosis. On one hand, the AASLD HCV guidance statement recommends HCC surveillance for this group, but on the other, the AASLD HCC guidance statement recommends surveillance only in presence of cirrhosis[16,20]. A recent study, using the Markov model, found out that HCC surveillance is cost-effective among CHC patients with cirrhosis but not for those with F3 fibrosis[21]. However, in clinical practice, the differentiation between advanced fibrosis (F3) and cirrhosis is not always straightforward. For this reason, EASL recommends HCC surveillance to patients with F3 fibrosis regardless of etiology, with a more clinically oriented approach. Given the limitations of the current surveillance protocols, several HCC risk scores have been developed mainly from Asian cohorts for patients with CHB. Even if in limited number, a few risk scores are also available for CHC or all-cirrhotic patients.

In this review, we summarize the characteristics and discuss the applicability of HCC-risk scores in clinical practice, with a special focus on chronic viral hepatitis. Several reviews investigated the impact of HCC risk scores on clinical practice in recent years, but newer scores and comparison studies have emerged since then[22-25]. Furthermore, new serologic biomarkers have been introduced for early detection of HCC with promising results, and some of them got involved in algorithms in combination with clinical and laboratory parameters.

**HCC RISK SCORES FOR CHB PATIENTS**

***Risk scores for untreated CHB patients***

The guide with age, gender, HBV-DNA, core promoter mutations, and cirrhosis (GAG-HCC) risk score was the first attempt to stratify HCC risk among CHB patients, which was published in 2009[26]. The study was conducted with 820 untreated CHB subjects (15% with cirrhosis) from Hong-Kong, and all patients were followed up for a median period of 77 mo. They showed that cirrhosis, age, gender, viral load, and precore mutation were independent predictors of HCC and used them all in the risk score. However, due to the unavailability of pre-core mutation assays in the routine clinical practice, they repeated the analysis without this variable and showed no loss of performance in the risk score. The area under the receiver-operating characteristics curve (AUROC) for GAG-HCC to predict HCC in 5 and 10 years was 0.87 and 0.88, respectively. The determined optimal cut-off value of 101 showed high sensitivity (88%) and specificity (78.7%) for the prediction of HCC at 10 years. Chinese University-HCC risk score (CU-HCC) was the second attempt for HCC risk stratification in CHB patients, which was published in 2010[27]. Using the same methodology, the investigators confirmed age, viral load, and cirrhosis as independent predictors of HCC during a median follow-up period of 10 years, with the addition of two markers of liver function (bilirubin and albumin). They proposed a three category risk score to distinguish low (< 5), intermediate (5-20), and high risk (> 20) CHB patients for HCC development. The model showed a good general performance in predicting 5- and 10-year HCC risk by showing AUROC values of 0.76 and 0.78, respectively. The 5-year HCC-free survival rates were 98.3%, 90.5%, and 78.9% in the low-, medium-, and high-risk groups, respectively. The determined cut-off value of 5 ruled out the risk of HCC development with high accuracy (negative predictive value [NPV] of 97.8% and 97.3 in training and validation cohorts, respectively), suggesting that HCC surveillance in low-risk group may not be cost-effective. Interestingly, the authors of GAG-HCC and CU-HCC, despite proposing their risk scores as tools to identify CHB patients at high risk for HCC development, never suggested their applicability in selecting candidates for HCC surveillance.

After two relatively small-sized studies, another HCC-risk score for untreated CHB patients without cirrhosis was proposed from Taiwan in 2010[28]. The risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score was developed in 3584 CHB Taiwanese patients without cirrhosis and validated in 1505 patients (18% of whom with cirrhosis) from Hong Kong and Korea[29]. The REACH-B score included male sex, age, alanine aminotransferase (ALT), hepatitis B e antigen (HBeAg), and HBV-DNA as parameters, but not cirrhosis, as the training cohort only consisted of patients without cirrhosis. Instead of using cut-off values, the score was proposed as a range from 0 to 17 points, with a progressively increasing risk of HCC development. The REACH-B score had a 5 and 10-year AUROC of 0.796 and 0.769 in the validation cohort. The 5 and 10-year AUROC values decreased to 0.698 and 0.647 in the analysis of the cirrhotic group only. This finding confirms that the presence of cirrhosis per se is a major determinant for HCC development. These findings suggest that the training cohort should reflect the overall population at HCC risk more balanced to produce a reliable score for use in clinical practice.

In the upcoming years, the score was revised (REACH-BII) with the inclusion of quantitative HBsAg, which proved to be an additional independent predictor for the development of HCC[30]. In 2014, REACH-B risk score went through a final modification in a South Korean cohort where liver stiffness measurement (LSM) by transient elastography substituted HBV-DNA level: the better performance of the modified score (AUROC values; mREACH-B: 0.814 *vs* REACH-B: 0.629) was consistent with the fact that the CHB patients included in the Korean study were under entecavir treatment[31]. Similar findings were reported by the investigators of the original REACH-B risk score study when they applied the old and modified score to CHB patients treated with nucleotide analogue[32].

Liver stiffness values, in addition to age, albumin and HBV-DNA were used by the group of investigators of the CU-HCC score in 2014, to develop a new score for untreated CHB patients, namely LSM-HCC[33]. The new scoring system ranged from 0 to 30, with an optimal cut-off value of 11 to identify patients at HCC risk. Patients with a LSM-HCC score lower than 11 had a very low 5-year risk for HCC, with 92% sensitivity, 71% specificity, and 100% NPV. In 2016, another HCC risk score was developed based on real-world data of 538 untreated CHB patients from Singapore, namely the real-world score-HCC (RWS-HCC)[34]. The RWS-HCC score included gender, age, cirrhosis, and AFP as independent predictors. Upon validation in 3353 patients from REACH-B, GAG-HCC and CU-HCC cohorts, RWS-HCC score had AUROC values of 0.767, 0.830, and 0.902 and NPV of 97.0%, 97.9%, and 93.0% respectively. In 2018, a novel score (HCC-ESC) was developed for 723 CHB patients who achieved HBeAg seroclearance; age, gender, cirrhosis, albumin, HBV-DNA, and ALT serum levels were the parameters of the risk score to identify the long-term risk. The HCC-ESC score showed an AUROC value of 0.92 in the validation cohort[35]. Finally, in 2019, another HCC risk score (AGED score) was proposed from a longer term (21-year follow-up period) cohort study[36]. The AGED score included age, gender, HBeAg status, and HBV-DNA as independent parameters. The AGED score categorized patients into three groups according to their HCC risk as low (0-4), intermediate (5-9), and high (10-12) risk using a 12-point score. A total of 1663 HBsAg-positive participants were recruited as the validation cohort, and the AGED score had AUROC values of 0.73 and 0.74.

***Risk scores for treated CHB patients***

At present, most CHB patients are under antiviral treatment, as it has a significant positive impact on the course of liver disease, reducing the progression to cirrhosis and its complications, including HCC[37,38]. Therefore, scores developed in cohorts of untreated CHB patients could not be adequate for treated patients because they include parameters that are not any more relevant in patients with sustained suppression of viral replication. PAGE-B is the first risk score developed in 1815 Caucasian CHB patients including those under nucleos(t)ide analogue (entecavir/tenofovir) treatment for at least 1 year[39]. This was a multicenter study where 1325 patients were set in derivation and 490 enrolled as validation cohort. The regression analysis identified age, gender, and platelet count as independent predictors of HCC. Cirrhosis was not included in the model, but the platelet count can be considered the surrogate marker for the cirrhotic (portal hypertension) stage. The c-statistic of PAGE-B score was found 0.82 in both the derivation and validation cohorts. Having a PAGE-B score < 9 (low risk), 10-17 (intermediate risk), > 18 (high risk) resulted in 5-year cumulative HCC incidences of 0%, 3%-4% and 16%-17%, respectively. The PAGE-B score shows a higher discriminatory ability in the identification of high-risk HBV patients from those with low-risk (100% NPV), contributing to define different surveillance strategies according to the individual risk. By contrast, the intermediate-risk group has to be considered as a borderline group, where the definition of individualized surveillance algorithm is more difficult. The original findings of the PAGE-B score were confirmed and validated in Spanish and South Korean cohorts[40,41]. In 2018, Kim *et al*[42] revised the PAGE-B risk score in 3001 Asian CHB patients receiving entecavir/tenofovir therapy by adding albumin to the PAGE-B risk score. They showed a significant improvement of prediction as compared to previous models, including CU-HCC, GAG-HCC, REACH-B, and PAGE-B, with an AUROC value of 0.82 at 5-year in HCC prediction and 100% NPV. Low- and intermediate-risk patients had an annual HCC development risk of approximately 0.2%-1%, which turned to be higher than 3% in the high-risk group. In an independent Asian HBV cohort, the mPAGE-B score showed similar accuracy with PAGE-B and GAG-HCC scores, but its discrimination ability was better than the REACH-B and CU-HCC scores[43]. PAGE-B and mPAGE-B risk scores showed promising results for adoption to HCC surveillance algorithm, particularly because of the very high NPV.

In 2017, the HCC-Risk Estimating Score in CHB patients under Entecavir (HCC-RESCUE) score based on age, gender, and cirrhosis was proposed for South Korean treated CHB patients[44]. The AUROC at 1, 3, and 5-year was 0.82, 0.81, and 0.81, respectively, in the validation cohort. In the same year, the age, platelet, AFP (APA)-B score was proposed from Taiwan[45]. It ranged from 0 to 15, with the optimal cut-off for low risk set at 6. The AUROCs for 2-, 3-, and 5-year HCC prediction was 0.939, 0.892, and 0.862, and the NPV for the low-risk group was 99.1% in the validation cohort.

In 2018, the cirrhosis, age, male gender, diabetes (CAMD) score, which aimed to predict HCC during antiviral treatment, was proposed by the analysis of population-wide data from the healthcare systems in Taiwan (training cohort of 23851 CHB patients) and Hong Kong (validation cohort of 19321 patients)[46]. The CAMD score was the first to integrate diabetes mellitus as a risk factor for HCC, extracted from the multivariable Cox proportional hazards model. These four parameters were weighed to develop the CAMD score ranging from 0 to 19 points, with the categorization of CHB patients in three groups as low (< 8), intermediate (9-12), and high (> 13) risk. Low-risk patients had an annual HCC incidence of 0.3%. The c-indices were higher than 0.75 within the first 5 years in the training and validation cohorts. The CAMD score can be easily computed with simple information at the baseline of treatment initiation.

In 2019, a multicenter study from Korea proposed the Age-Albumin-Sex-Liver cirrhosis (AASL-HCC) score[47]. Age, albumin, male gender, and cirrhosis were extracted as independent predictors of HCC development while under entecavir or tenofovir treatment in a cohort of 1242 consecutive treatment-naive HBV patients, who were followed from 2007 to 2017. Low (< 5), intermediate (6-19), and high (> 20) risk groups showed HCC incidence rates of 0%, 3.7%-7.4%, and 17.6%-30.9%, respectively. The AUROC value for HCC prediction in 3-year, 5-year and total follow-up period was 0.850, 0.805, and 0.797, respectively, in the validation cohort.

In 2020, a multicenter study, enrolling 8048 Asian CHB patients under antiviral treatment from 25 centers in the United States and Asian-Pacific region, developed the REAL-B score[48]. It includes seven variables (male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and AFP) to categorize patients into the following three groups: those at low (0-3), moderate (7), and high (8-13) risk. All AUROCs for HCC prediction were higher than 0.8 at 3, 5, and 10 years, with a better predictive performance than PAGE-B in the same cohort (AUROC values at same time points; 0.73-0.74). The previously described HCC-ESC score was revised in 2020 in a Korean cohort of CHB patients under antiviral treatment and called HCC-ESCAVT[49]. The risk score targeted CHB patients with HBeAg seroclearance like the original version and used the following three parameters: male gender, cirrhosis, and fibrosis-4 index. The AUROC values for 5-year HCC prediction were 0.770 and 0.774 in the training and validation cohorts, respectively.

***Interpretation and comparison of CHB-specific HCC risk scores***

CHB specific HCC risk scores are summarized in Table 2. Most of them had been developed in Asian CHB patients, resulting from the urgency to have an accurate, precise, simple-to-use HCC risk score to be used in routine clinical activity, particularly in geographical areas where the burden of HBV infection is higher. The majority were developed in Asian patients and were also validated in Caucasians with acceptable performance. Nevertheless, most validation performances were lower than in the training cohort. Accordingly, the validation studies with Caucasian CHB patients showed AUROC values ranging from 0.74 to 0.86 for GAG-HCC, 0.62 to 0.91 for CU-HCC, 0.54 to 0.77 for REACH-B, and 0.85 for RWS-HCC risk scores[41,50-54]. These findings indicate that specific features of the population significantly influence the risk of HCC development. On the other hand, it is well known that the duration of HBV infection and florid viral replication, HBV genotype, exposure to other oncogenic factors (such as aflatoxins), and co-morbidities play a relevant role in HCC development[14]. As a consequence, a universal and highly accurate HCC score is unrealistic. Conversely, a predictive model based on data reflecting the virologic and clinical features of a given geographical area will provide a reliable tool for the same specific population. Nevertheless, such a model will require continuous adjustments reflecting the dynamic variations of the population based on the changing patterns of both HBV epidemiology and cirrhosis prevalence, HBV population aging, the variable impact of antiviral treatment according to its timing during the CHB course, and the variations of all the other co-factors of liver disease. Accordingly, the GAG-HCC, CU-HCC, REACH-B, LSM-HCC, and RWS-HCC scores, all derived from untreated CHB cohorts, as they were developed from patients followed in the 1990s or early 2000s, are not any more of interest because at present most of HBsAg carriers with evidence of CHB are under antiviral therapy. Another vital issue is the prevalence of cirrhosis in the studied cohorts, which may modify and alter the power of other parameters significantly involved in the scoring systems. The best example for this issue is that the REACH-B score, derived from a cohort of purely non-cirrhotic patients, has degraded performance in validation studies involving cirrhotic patients. In general, all the validated risk scores showed high NPV (95% to 100%) in both the original and external validation cohorts, suggesting redundancy of standard surveillance strategy to low-risk groups. The high-risk groups showed a wide range of annual HCC incidence, ranging from 2.3% to 9.2%, in CHB specific risk scores. By contrast, it indicates that we require additional studies to stratify the individual risk and define new surveillance strategies with more sensitive imaging or serologic tools.

In conclusion, risk stratification is attainable by validated HCC risk scores, but the optimal performance is obtained only in populations with similar characteristics to those where the score was developed. Besides, continuous validation of the predictive models is required to adjust them according to the dynamic variation of all factors influencing the individual HCC risk.

**HCC RISK SCORES FOR CHC PATIENTS**

As compared to CHB, there are a few proposed modeling studies in CHC patients to predict their HCC risk (Table 3), and their major limitation is the lack of external validation cohorts for most. The latter drawback for their use in clinical practice is the heterogeneity of CHC patients. It may be due to different co-factors affecting the disease progression of HCV and different prevalence across the world. Furthermore, the availability of DAAs in clinical practice acted as a watershed in the clinical needs to optimize the management of CHC patients with advanced fibrosis or cirrhosis; the current unmet need is an algorithm to guide the clinician to personalize the surveillance according to the residual HCC risk. The antiviral treatment proved useful to improve the outcome of CHC and reduce the HCC incidence since the introduction of interferon and ribavirin[55]. However, patients with advanced liver disease had a significantly lower SVR rate and reduced compliance to treatment. Thus, the availability of scoring systems to identify individuals at higher risk of HCC development among those with advanced liver disease was perceived as a major clinical interest.

The first HCC risk score attempt was derived from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis cohort in 2009[56]. During a median follow-up of 4.6 years, 48 of 1005 (4.8%) patients developed HCC, with a 5-year HCC incidence comparable in peginterferon-treated or untreated patients (5.4% *vs* 5.0%). The presence of cirrhosis together with older age, Black race, lower platelet count, higher alkaline phosphatase, esophageal varices, and smoking status identified patients at higher risk. A few years later, another study conducted on 11721 HCV-related cirrhotic patients from the Veterans Administration Hepatitis C Virus Clinical Case Registry in the United States investigated the possibility to develop an AFP-based algorithm where biomarkers of disease activity (ALT) and disease stage (platelet count) were used to adjust the predictive accuracy of AFP[57]. At any given AFP value, low numbers of platelets and ALT and older age were associated with increased risk of HCC, and high levels of ALT and normal/high numbers of platelets were associated with low risk for HCC. The advantage of the model was its inclusion of routine laboratory tests and easy to manage parameters.

Two studies from Asia tackled the same issue with different approaches. Masuzaki *et al*[58] investigated the possibility to use LSM determined by FibroScan as a predictor of HCC in 866 HCV-infected patients. The cohort was prospectively followed for a mean period of 3 years after initial LSM determination. The odds ratio of HCC development was correlated with increasing LSM, and a LSM cut-off value of > 15 kPa had a greater association with HCC development. The other study from Taiwan enrolled 871 biopsy-proven CHC patients who achieved sustained response after peginterferon and ribavirin. They integrated the histologic fibrosis status with other parameters (age, AFP, low platelet counts) to define a HCC risk score[59]. Accordingly, low (< 10), intermediate (11-15), and high (> 16) risk groups had 1.37%, 9.14%, and 30.7% chances of HCC development, respectively. The authors proposed their novel risk score for HCC screening in CHC patients achieving SVR.

In 2016, a multicenter French cohort (ANRS CO12 CirVir) study with 1323 CHC-related cirrhosis patients was conducted to develop an individualized score for HCC prediction[60]. An 11-point risk score was established using the five variables independently associated with HCC (age > 50 years, past excessive alcohol intake, low platelet count, gamma-glutamyltransferase (GGT) > upper limit of normal, and absence of SVR). This new risk score was able to stratify the CHC-cirrhosis population into three groups according to HCC risk as low (< 3), intermediate (4-7), and high (> 8) risk. However, this score also lacked external validation.

In 2020, a different approach was used to refine HCC risk among patients with CHC-related cirrhosis from the same French cohort, by applying predictive machine learning approaches (Fine-Gray regression model) rather than traditional multivariate linear regression analysis[61]. The study was interesting in terms of bringing a new breath to risk-stratification models and personalized HCC-surveillance efforts. As expected, the authors showed that factors influencing the HCC risk varied after SVR. Only elevated AST, low platelet count, and shorter prothrombin time was independently associated with HCC risk after SVR, whereas there were six independent predictors (past excessive alcohol intake, genotype 1, elevated AFP, GGT, low platelet count, and albumin levels) before SVR. However, the interactions between the different parameters were quite complex, and eight different groups were identified with varying cancer risks and predictors depending on SVR achievement. The findings were interesting but not yet directly applicable in clinical practice. Nevertheless, the study showed that machine learning algorithms can refine the HCC risk assessment by revealing complex interactions between cancer predictors and eventually prompting more cost-effective tailored surveillance programs development.

An absolute simplified model was derived and proposed from 1088 Japanese CHC patients who achieved SVR after DAA in the same year[62]. They revealed age and AFP as independent predictors of HCC after achieving SVR with DAAs. Using AFP and age only, they developed a scoring system (0-2 points) where the incidence of HCC at 2-years was 0.3% in the 0 points group, 6.27% in the 1-point group, and 18.37% in the 2-points group. This oversimplified approach is captivating; however, external validation in different populations is required, as specific features, such as HCV epidemiology in the geographical area, could significantly influence the findings. The General Evaluation Score (GES) was recently proposed by a study performed in Egypt on 4400 patients, with cirrhosis or advanced fibrosis who achieved a SVR[63]. Age, sex, serum albumin, AFP and, pretreatment fibrosis stage was identified as risk factors for HCC and used to construct the risk score, and categorized CHC patients into three groups. The 2-year cumulative HCC incidence was 1.2%, 3.3%, 7.1% for low-, medium-, and high-risk groups, respectively. The GES score had high predictive ability in internal and external validation cohorts from Egypt with c-statistics values of 0.80 and 0.81. Unfortunately, the findings of this interesting and promising study cannot be generalized because it included only HCV genotype 4-infected patients.

Overall, it appears that in the setting of CHC patients from one side, the proposed scoring systems are lacking adequate external validation, which is mandatory to warrant their use in clinical practice. Furthermore, the high variability of the epidemiology of HCV infection (different genotype distribution worldwide, distinct modalities of HCV spreading in the various geographical area and overtime) is even more complicated than in HBV, necessitating the implementation of a model in a different context. Nevertheless, the evidence that the risk of HCC significantly declines over time in patients who achieved SVR underlines the urgent need for new algorithms to personalize the HCC surveillance and optimize its cost/benefit.

**PREDICTION OF HCC RISK FOR PATIENTS WITH CLD OR OTHER RISK FACTORS**

HCC prediction risk scores, regardless of underlying liver disease etiology, are summarized in Table 4. Flemming *et al*[64] developed an HCC risk prediction model to estimate the 1-year probability of HCC to assist clinicians with patient counseling by studying a large cohort of patients (*n* = 34932) with cirrhosis from the United States liver transplantation waiting list database. Thus, the authors did not mean to create a score to modify the surveillance of cirrhotic patients but to provide an individualized approach to HCC counseling based on specific patient characteristics. They identified six baseline variables (age, diabetes, race, etiology of cirrhosis, sex, and severity [ADRESS] of liver dysfunction) independently associated with HCC and the c-indices of the ADRESS-HCC risk model were 0.704 and 0.691 in the derivation and internal validation cohorts, respectively. The major limitation of the study was the selection of patients with advanced liver disease, as they were cirrhotic already on the transplant waitlist. In 2017, the Toronto Hepatocellular carcinoma Risk Index (THRI) was developed to predict 10-year HCC risk, using simple clinical and laboratory parameters (age, gender, etiology, platelet)[65]. The THRI weighed etiologies, including the SVR status of HCV-related cirrhosis, and its performance had been studied in three external validation cohorts from different regions (Netherlands, China, Turkey) with similar accuracy in predicting HCC development[65-67]. All AUROC values ranged from 0.75 to 0.80, using the same cut-off value of 240 to identify the high-risk HCC group.

Diabetes is a risk factor for HCC in patients with CLD. Li *et al*[68] in 2018 approached the issue in the other way round, developing a risk score system to predict the HCC risk in patients with diabetes. They studied a cohort of 31723 Taiwanese patients with type 2 diabetes mellitus, followed-up for 8.3 years, and the final model (scores ranging from -6 to 40 points) included age, gender, smoking status, hemoglobin A1c, glutamic-pyruvic transaminase, cirrhosis, hepatitis B, hepatitis C, anti-diabetic and anti-hyperlipidemic medications, and total/high-density lipoprotein cholesterol ratio. The 3-, 5-, and 10-year AUROC values to predict HCC risk were 0.81, 0.80, and 0.77.

More recently, an ambitious study aimed to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis, published by an international study group. A total of 17374 patients (10578 Asian and 2510 Caucasian treated CHB patients, 3566 CHC; 2489 of whom with cirrhosis and SVR, and 720 patients with non-viral hepatitis) from 11 international prospective observational cohorts or randomized controlled trials were analyzed[69]. This study is unique in terms of having a large validation cohort from several ethnicities and etiologies; however, the majority were still CHB patients. The aMAP score was obtained from a training cohort of 3688 Asian patients and validated in nine cohorts with different etiologies and ethnicities. The score ranges from 0 to 100 and involves age, male, albumin-bilirubin score, and platelet count; the value of 50 was identified as the optimal cut-off to predict HCC, with a sensitivity of 85.7%-100% and 99.3%-100% NPV. The authors proposed their risk score, based on five common parameters, showing high performance regardless of etiology and ethnicity, as a potential new tool to establish a risk score-guided HCC surveillance strategy worldwide.

**TUMOR MARKERS AND HCC RISK SCORES**

Several serologic biomarkers, other than AFP that have already been discussed and included in some scoring systems, such as osteopontin, alpha-fetoprotein-L3 (AFP-L3), des-gamma-carboxy prothrombin (DCP), also known as the protein induced by vitamin K absence or antagonist II (PIVKAII), glypican-3, alpha-1-fucosidase, midikine, dikkopf-1, Golgi protein-73, squamose cell carcinoma antigen, and fucosylated glycoprotein, have been investigated for their potential role in HCC screening. Ideally, blood-based biomarkers with adequate sensitivity or specificity could enable early detection of HCC, avoiding cumbersome ultrasound-based surveillance. However, at present, none of the biomarkers has been validated in phase III clinical trials and are used in clinical practice, with the exclusion of AFP and PIVKAII, recommended by Japanese HCC guidelines, particularly in Japan[70]. This can be explained by the high heterogeneity of HCC biology, where several pathway alterations are involved in the tumorigenesis process[71]. Therefore, the combination of different biomarkers and the available clinical and laboratory variables has been evaluated to develop predictive scores (Table 5).

The GALAD algorithm combining three biomarkers (AFP, AFP-L3, and DCP) with sex and age showed a remarkable overall performance (AUROC values of 0.95, 92% sensitivity, and 85% specificity) that remained high (AUROC: 0.92, sensitivity 92%, specificity 79%) for early HCC detection[72]. The model was validated in independent cohorts from Japan, Germany, and Hong Kong, with overall sensitivity ranging from 80%-91%, specificity from 81%-90%, and AUROC values from 0.85 to 0.95[73]. Both in the original and validation studies, the etiologies were mixed and dominantly consisted of alcohol-related liver disease and CHC patients. The homogeneity of the studied cohorts as far as the etiology of CLD is concerned is critical as the diagnostic performance of the most widely used standardized HCC biomarkers, namely AFP and PIVKAII is significantly influenced by the etiology and activity of CLD, and their combination provides a better diagnostic accuracy[74]. Interestingly, the GALAD score showed an AUC of 0.96 in the identification of HCC in a German cohort of patients with nonalcoholic steatohepatitis (NASH), with comparable performance in patients with or without cirrhosis. A cut-off value of -0.63 GALAD score identified patients with HCC within Milan Criteria with an AUC of 0.91 (68% sensitivity and 93% specificity). The same threshold had been proposed to identify NASH patients who will have imaging diagnosis 200 d later. The GALAD score performance for HCC detection was also compared with liver US and showed to be superior. The combination of GALAD and US score further improved the performance score in a single-center cohort, achieving an area under the curve of 0.98[75]. Overall, these findings indicate that the GALAD score can detect patients with early-stage HCC and might facilitate surveillance of patients, particularly those with NASH, who are often obese, which limits the sensitivity of detection of liver cancer by US. However, the optimal cut-off value has to be defined to develop a shared and standardized surveillance algorithm. Another risk score, namely the Doylestown algorithm, incorporates two biomarkers (AFP and fucosylated kininogen) with two clinical (age, gender) and two laboratory (ALT and alkaline phosphatase) variables[76]. The Doylestown algorithm had an 89% detection rate for early HCCs with an AUROC value of 0.97 in low-AFP patients. The promising results of the Doylestown algorithm require adequate validation in larger and adequate cohort series.

In 2015, White *et al*[77] published an adjusted AFP-based algorithm for HCC detection in patients with HCV-related cirrhosis. It was the implementation of a previously reported score where age, platelets, ALT values, and interaction terms (AFP and ALT, and AFP and platelets) were used. In the new model, serial AFP measurements were included, showing an improvement in the overall performance. More recently, the Hospital Episode Statistics (HES) algorithm was validated in a cohort, which included 33627 patients with cirrhosis of any etiology who did not develop HCC during follow-up (controls) and 4804 patients with incident HCC (cases)[78]. At 90% specificity, the HES algorithm identified HCC cases with 52.56% sensitivity, compared to 48.13% sensitivity for the AFP assay alone, within 6 mo before diagnosis, which was an absolute improvement of 4.43% (*P* < 0.0005). Overall,the algorithm offers a modest advantage over AFP alone in HCC surveillance. The findings were substantially confirmed in a subsequent study, where the etiology of cirrhosis was added to the model[79].

**POTENTIAL MOLECULAR CANDIDATES FOR INTEGRATION TO HCC RISK SCORES**

Several lines of research are aiming to identify new biomarkers for detection of HCC at a very early stage. CancerSEEK is a recently proposed platform assessing eight circulating proteins (CA125, CEA, CA19-9, prolactin, hepatocyte growth factor, osteopontin, myeloperoxidase, and tissue inhibitor of metalloproteinases 1) and mutations in cell-free DNA[80]. By a machine-learning approach, an algorithm was developed with an overall sensitivity of 70% and a specificity of 99% in detecting eight cancers, including HCC. A major limitation is that the study enrolled known cancers, whereas the aim would be to identify HCC in asymptomatic patients. Furthermore, using cancer gene panels in cell-free DNA could give rise to a high number of false-positive in healthy individuals[81]. A large number of other biomarkers, such as circulating tumor cells, microRNAs, tumor cell-free DNAs, tumor-derived/associated extracellular vesicles, metabolites, and proteins, are under investigation to obtain a liquid biopsy for HCC[82]. Another interesting approach has been proposed recently by Liu *et al*[83], who showed that a viral exposure signature (VES) obtained by a synthetic viral scan technology of viral antibodies could discriminate HCC with high confidence from at-risk individuals (area under the curve of 0.91 at baseline and 0.98 at diagnosis) or healthy volunteers. The VES was validated in at-risk patients in a prospective HCC cohort; however, larger prospective studies are needed to evaluate its utility in HCC surveillance.

Finally, germ-line single gene polymorphisms have also been analyzed in genome-wide association studies as specific host factors that determine HCC susceptibility for chronic viral hepatitis patients. *EGF, IFNL3, MICA, TLL1, MERTK, K27 of histone H3-H3K27ac* for CHC[84-90], and *KIF1B, STAT4,* and *HLA-DQB1/HLA-DBA2* for CHB patients were the most promising ones[91,92]*.* It is not very likely that a single germ-line genetic variant may affect HCC development in chronic viral hepatitis, but future attempts may include integrating them into HCC-risk scales. The future efforts will be incorporating molecular profiling into HCC-surveillance algorithms that could also identify targets for potential chemo-preventive interventions.

**CONCLUSION**

The epidemiology of CLD is rapidly changing, with a progressive reduction of viral hepatitis burden and an increase of non-alcoholic fatty liver diseases (NAFLD). Considering the significant rise in NAFLD-related HCC cases globally, the ability to stratify the risk of HCC is becoming another urgent need. HCC does also occur in patients with non-cirrhotic NAFLD but surveillance is not recommended to this group as incidence rates are lower than 1% a year[93]. The HCC risk stratification tools in patients with NAFLD is not discussed here, as the aim of the present article is to focus on HCC surveillance of patients with chronic viral hepatitis. The incidence of HCC has become highly heterogeneous within patients with chronic viral hepatitis since it differs significantly according to the period of both viral infection, the beginning of treatment, and the rate of cirrhosis. As a consequence, the incidence of HCC differs according to the geographical distribution of risk factors. Thus, the identification of appropriate tools for tailoring the HCC screening decisions according to the different subgroups of patients based on the CLD etiology, relevant clinicopathologic and epidemiologic factors is a growing need in clinical practice. The individually tailored HCC surveillance would imply a cost-effective application of personalized protocols using highly sensitive imaging techniques[94]. However, such an important medical need remains currently unmet and it appears unlikely that it will be fulfilled by a universal generalized score. The HCC-risk stratification models appear helpful to generate reliable and personalized HCC predictive scores only if the scoring system is applied to cohorts whose clinic-pathologic characteristics are highly similar to those of the original discovery cohort for the particular model.

On the other hand, the more widespread use of current HCC biomarkers to increase the specificity for identifying patients with a more significant risk is controversial. All HCC markers so far identified have a highly dis-homogeneous prevalence in patients with different etiology of CLD that imposes their use in multiple markers panels. Furthermore, the serum levels of HCC biomarkers change over time, and the detection of this velocity might improve their specificity. Their analytical cut-off needs to be better standardized in this regard. For instance, the levels of AFP are influenced by liver regeneration prompted by flares of intrahepatic necroinflammation; thus, the range of AFP normality values vary consistently from patients with chronic viral hepatitis and sustained antiviral response to those with metabolic-associated fatty liver disease and ongoing steatohepatitis. Future studies should address these issues using, for instance, algorithms of the combined dynamics of ALT and AFP levels.

In conclusion, according to existing knowledge, there is a strong recommendation to perform surveillance in patients with cirrhosis regardless of their liver disease etiology, origin, age, and sex. The question remains as to whether the time intervals of US screening can be safely reduced in lower risk cirrhotic patients who recovered from chronic viral hepatitis and maintain normal liver function tests after sustained response to antiviral therapy. The issue of HCC surveillance is much more complicated in patients without cirrhosis. An ideal risk score system should define optimal cut-off values to discriminate high-risk HCCs with high annual HCC incidence (> 3%-5%) and high PPV and low-risk HCCs with high NPV (> 99%). Most of the existing risk scores for CHB reached or were close to this performance, but they did not target the non-cirrhotic patients specifically and were highly dis-homogeneous for the cirrhosis rate. For HCC-risk scores specific for CHC patients without cirrhosis, there is a lack of validation in independent cohorts and proposed scores are not yet representative of CHC patients with complete SVR in the current era of DAAs. Currently proposed HCC-risk scores are not yet standardized to be incorporated into sustainable HCC-surveillance decision algorithms, and more efforts should be made to personalize HCC surveillance in CHB patients without cirrhosis and CHC patients with F3 fibrosis, at least in the near future. Patients with cirrhosis have to undergo HCC-surveillance regardless of liver disease etiology and prospective, large-scale multinational study with stratification on the basis of underlying CLD etiology, fibrosis status, ethnicity (including Africans and other parts of the world) are required. The potential of such a study must include a dynamic calculation of HCC-risk scores every 6 mo. Individual molecular profiling will provide a crucial integration of HCC-surveillance decision algorithms and help identify high-risk target populations in the future, but they are currently not widely available.

**REFERENCES**

1 **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

2 **Ioannou GN**, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2007; **5**: 938-945, 945.e1-945.e4 [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039]

3 **Sangiovanni A**, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology* 2006; **43**: 1303-1310 [PMID: 16729298 DOI: 10.1002/hep.21176]

4 **Global Burden of Disease Liver Cancer Collaboration.**, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. *JAMA Oncol* 2017; **3**: 1683-1691 [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055]

5 **Garuti F**, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F; ITA.LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update. *Liver Int* 2021; **41**: 585-597 [PMID: 33219585 DOI: 10.1111/liv.14735]

6 **Desai A**, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. *World J Hepatol* 2019; **11**: 1-18 [PMID: 30705715 DOI: 10.4254/wjh.v11.i1.1]

7 **Papatheodoridis GV**, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. *J Hepatol* 2015; **62**: 956-967 [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002]

8 **Falade-Nwulia O**, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Ann Intern Med* 2017; **166**: 637-648 [PMID: 28319996 DOI: 10.7326/M16-2575]

9 **Ioannou GN**, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol* 2017 [PMID: 28887168 DOI: 10.1016/j.jhep.2017.08.030]

10 **Kanwal F**, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. *Gastroenterology* 2017; **153**: 996-1005.e1 [PMID: 28642197 DOI: 10.1053/j.gastro.2017.06.012]

11 **Kanwal F**, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. *Hepatology* 2020; **71**: 44-55 [PMID: 31222774 DOI: 10.1002/hep.30823]

12 **Singal AG**, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J Hepatol* 2020; **72**: 250-261 [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025]

13 **McCabe C**, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. *Pharmacoeconomics* 2008; **26**: 733-744 [PMID: 18767894 DOI: 10.2165/00019053-200826090-00004]

14 **Fattovich G**, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol* 2008; **48**: 335-352 [PMID: 18096267 DOI: 10.1016/j.jhep.2007.11.011]

15 **Omata M**, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; **11**: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

16 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]

17 **Terrault NA**, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; **67**: 1560-1599 [PMID: 29405329 DOI: 10.1002/hep.29800]

18 **European Association for the Study of the Liver.** Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

19 **Bruix J**, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]

20 **AASLD-IDSA HCV Guidance Panel**. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis* 2018; **67**: 1477-1492 [PMID: 30215672 DOI: 10.1093/cid/ciy585]

21 **Farhang Zangneh H**, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. *Clin Gastroenterol Hepatol* 2019; **17**: 1840-1849.e16 [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018]

22 **Sherman M**. HCC Risk Scores: Useful or Not? *Semin Liver Dis* 2017; **37**: 287-295 [PMID: 29272891 DOI: 10.1055/s-0037-1607452]

23 **Wong VW**, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? *J Hepatol* 2015; **63**: 722-732 [PMID: 26026875 DOI: 10.1016/j.jhep.2015.05.019]

24 **Lee HW**, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. *World J Gastroenterol* 2016; **22**: 8314-8321 [PMID: 27729738 DOI: 10.3748/wjg.v22.i37.8314]

25 **Voulgaris T**, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. *Liver Int* 2020; **40**: 484-495 [PMID: 31884726 DOI: 10.1111/liv.14334]

26 **Yuen MF**, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 2009; **50**: 80-88 [PMID: 18977053 DOI: 10.1016/j.jhep.2008.07.023]

27 **Wong VW**, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol* 2010; **28**: 1660-1665 [PMID: 20194845 DOI: 10.1200/JCO.2009.26.2675]

28 **Yang HI**, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *J Clin Oncol* 2010; **28**: 2437-2444 [PMID: 20368541 DOI: 10.1200/JCO.2009.27.4456]

29 **Yang HI**, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011; **12**: 568-574 [PMID: 21497551 DOI: 10.1016/S1470-2045(11)70077-8]

30 **Lee MH**, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ; R.E.V.E.A.L.-HBV Study Group. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. *Hepatology* 2013; **58**: 546-554 [PMID: 23504622 DOI: 10.1002/hep.26385]

31 **Lee HW**, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. *Am J Gastroenterol* 2014; **109**: 1241-1249 [PMID: 24957159 DOI: 10.1038/ajg.2014.157]

32 **Yang HI**, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, Chan HL, Kao JH, Chen CJ. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. *Clin Gastroenterol Hepatol* 2016; **14**: 461-468.e2 [PMID: 26598229 DOI: 10.1016/j.cgh.2015.10.033]

33 **Wong GL**, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. *J Hepatol* 2014; **60**: 339-345 [PMID: 24128413 DOI: 10.1016/j.jhep.2013.09.029]

34 **Poh Z**, Shen L, Yang HI, Seto WK, Wong VW, Lin CY, Goh BB, Chang PE, Chan HL, Yuen MF, Chen CJ, Tan CK. Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. *Gut* 2016; **65**: 887-888 [PMID: 26786688 DOI: 10.1136/gutjnl-2015-310818]

35 **Fung J**, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. *Hepatology* 2018; **68**: 462-472 [PMID: 29534307 DOI: 10.1002/hep.29874]

36 **Fan C**, Li M, Gan Y, Chen T, Sun Y, Lu J, Wang J, Jin Y, Lu J, Qian G, Gu J, Chen J, Tu H. A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China. *Gut* 2019; **68**: 948-949 [PMID: 29720409 DOI: 10.1136/gutjnl-2018-316525]

37 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

38 **Yip TC**, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. *Gastroenterology* 2020; **158**: 215-225.e6 [PMID: 31574268 DOI: 10.1053/j.gastro.2019.09.025]

39 **Papatheodoridis G**, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016; **64**: 800-806 [PMID: 26678008 DOI: 10.1016/j.jhep.2015.11.035]

40 **Kim MN**, Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. *Liver Int* 2017; **37**: 1788-1795 [PMID: 28418595 DOI: 10.1111/liv.13450]

41 **Riveiro-Barciela M**, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-Samaniego J, Rivero M, Acero D, Fernandez-Bermejo M, Moreno D, Sánchez-Pobre P, de Cuenca B, Moreno-Palomares JJ, Esteban R, Buti M. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. *Dig Dis Sci* 2017; **62**: 784-793 [PMID: 28078526 DOI: 10.1007/s10620-017-4448-7]

42 **Kim JH**, Kim YD, Lee M, Jun BG, Kim TS, Suk KT, Kang SH, Kim MY, Cheon GJ, Kim DJ, Baik SK, Choi DH. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. *J Hepatol* 2018; **69**: 1066-1073 [PMID: 30075230 DOI: 10.1016/j.jhep.2018.07.018]

43 **Lee HW**, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. *Liver Int* 2019; **39**: 1624-1630 [PMID: 31050379 DOI: 10.1111/liv.14129]

44 **Sohn W**, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. *Clin Mol Hepatol* 2017; **23**: 170-178 [PMID: 28506056 DOI: 10.3350/cmh.2016.0086]

45 **Chen CH**, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. *Oncotarget* 2017; **8**: 92431-92441 [PMID: 29190928 DOI: 10.18632/oncotarget.21369]

46 **Hsu YC**, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *J Hepatol* 2018; **69**: 278-285 [PMID: 29551708 DOI: 10.1016/j.jhep.2018.02.032]

47 **Yu JH**, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR, An HY, Lee JW. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. *Eur J Gastroenterol Hepatol* 2019; **31**: 865-872 [PMID: 30694912 DOI: 10.1097/MEG.0000000000001357]

48 **Yang HI**, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. *J Infect Dis* 2020; **221**: 389-399 [PMID: 31550363 DOI: 10.1093/infdis/jiz477]

49 **Lim TS**, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee JW, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. *J Viral Hepat* 2020; **27**: 1052-1060 [PMID: 32383246 DOI: 10.1111/jvh.13316]

50 **Papatheodoridis GV**, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015; **62**: 363-370 [PMID: 25195548 DOI: 10.1016/j.jhep.2014.08.045]

51 **Arends P**, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. *Gut* 2015; **64**: 1289-1295 [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023]

52 **Abu-Amara M**, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H, Wong DK, Janssen HL, Feld JJ. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. *Gut* 2016; **65**: 1347-1358 [PMID: 25934760 DOI: 10.1136/gutjnl-2014-309099]

53 **Brouwer WP**, van der Meer AJP, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, Ten Kate FJW, Janssen HLA, Hansen BE. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. *J Viral Hepat* 2017; **24**: 1023-1031 [PMID: 28544398 DOI: 10.1111/jvh.12727]

54 **Daheim M**, Lang S, Goeser T, Steffen HM, Demir M. Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia. *Gut* 2017; **66**: 1346-1347 [PMID: 27670373 DOI: 10.1136/gutjnl-2016-312993]

55 **Yu ML**, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. *Antivir Ther* 2006; **11**: 985-994 [PMID: 17302368]

56 **Lok AS**, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology* 2009; **136**: 138-148 [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014]

57 **El-Serag HB**, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. *Gastroenterology* 2014; **146**: 1249-55.e1 [PMID: 24462733 DOI: 10.1053/j.gastro.2014.01.045]

58 **Masuzaki R**, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009; **49**: 1954-1961 [PMID: 19434742 DOI: 10.1002/hep.22870]

59 **Chang KC**, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. *J Antimicrob Chemother* 2012; **67**: 2766-2772 [PMID: 22899800 DOI: 10.1093/jac/dks269]

60 **Ganne-Carrié N**, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). *Hepatology* 2016; **64**: 1136-1147 [PMID: 27348075 DOI: 10.1002/hep.28702]

61 **Audureau E**, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Chazouillères O, Mallat A, Grangé JD, Attali P, d'Alteroche L, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Pol S, Nahon P; ANRS CO12 CirVir group. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. *J Hepatol* 2020; **73**: 1434-1445 [PMID: 32615276 DOI: 10.1016/j.jhep.2020.05.052]

62 **Tani J**, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. *Oncol Lett* 2020; **19**: 2205-2212 [PMID: 32194718 DOI: 10.3892/ol.2020.11341]

63 **Shiha G**, Waked I, Soliman R, Elbasiony M, Gomaa A, Mikhail NNH, Eslam M. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. *Liver Int* 2020; **40**: 2828-2833 [PMID: 32946647 DOI: 10.1111/liv.14666]

64 **Flemming JA**, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. *Cancer* 2014; **120**: 3485-3493 [PMID: 25042049 DOI: 10.1002/cncr.28832]

65 **Sharma SA**, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. *J Hepatol* 2017 [PMID: 28844936 DOI: 10.1016/j.jhep.2017.07.033]

66 **Zhang H**, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. *World J Surg Oncol* 2019; **17**: 75 [PMID: 31039803 DOI: 10.1186/s12957-019-1619-3]

67 **Demirtas CO**, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. *Eur J Gastroenterol Hepatol* 2020; **32**: 882-888 [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685]

68 **Li TC**, Li CI, Liu CS, Lin WY, Lin CH, Yang SY, Lin CC. Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study. *Semin Oncol* 2018; **45**: 264-274 [PMID: 30342872 DOI: 10.1053/j.seminoncol.2018.07.006]

69 **Fan R**, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. *J Hepatol* 2020; **73**: 1368-1378 [PMID: 32707225 DOI: 10.1016/j.jhep.2020.07.025]

70 **Kokudo N**, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. *Hepatol Res* 2019; **49**: 1109-1113 [PMID: 31336394 DOI: 10.1111/hepr.13411]

71 **Craig AJ**, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 139-152 [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4]

72 **Johnson PJ**, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 144-153 [PMID: 24220911 DOI: 10.1158/1055-9965.EPI-13-0870]

73 **Berhane S**, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. *Clin Gastroenterol Hepatol* 2016; **14**: 875-886.e6 [PMID: 26775025 DOI: 10.1016/j.cgh.2015.12.042]

74 **Ricco G**, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. *Cancer Biomark* 2018; **21**: 603-612 [PMID: 29278878 DOI: 10.3233/CBM-170551]

75 **Yang JD**, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. *Cancer Epidemiol Biomarkers Prev* 2019; **28**: 531-538 [PMID: 30464023 DOI: 10.1158/1055-9965.EPI-18-0281]

76 **Wang M**, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. *Cancer Prev Res (Phila)* 2016; **9**: 172-179 [PMID: 26712941 DOI: 10.1158/1940-6207.CAPR-15-0186]

77 **White DL**, Richardson P, Tayoub N, Davila JA, Kanwal F, El-Serag HB. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. *Gastroenterology* 2015; **149**: 1986-1987 [PMID: 26519622 DOI: 10.1053/j.gastro.2015.10.004]

78 **Tayob N**, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. *Clin Gastroenterol Hepatol* 2019; **17**: 1886-1893.e5 [PMID: 30557738 DOI: 10.1016/j.cgh.2018.12.005]

79 **Tayob N**, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. *Clin Gastroenterol Hepatol* 2021; **19**: 1443-1450.e6 [PMID: 32768590 DOI: 10.1016/j.cgh.2020.07.065]

80 **Cohen JD**, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science* 2018; **359**: 926-930 [PMID: 29348365 DOI: 10.1126/science.aar3247]

81 **Liu J**, Chen X, Wang J, Zhou S, Wang CL, Ye MZ, Wang XY, Song Y, Wang YQ, Zhang LT, Wu RH, Yang HM, Zhu SD, Zhou MZ, Zhang XC, Zhu HM, Qian ZY. Biological background of the genomic variations of cf-DNA in healthy individuals. *Ann Oncol* 2019; **30**: 464-470 [PMID: 30475948 DOI: 10.1093/annonc/mdy513]

82 **King LY**, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. *Gut* 2015; **64**: 1296-1302 [PMID: 25143343 DOI: 10.1136/gutjnl-2014-307862]

83 **Liu J**, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, Kim Y, Bowman ED, Ambs S, Zhao Y, Tran B, Wu X, Koh C, Surana P, Liang TJ, Guarnera M, Mann D, Rajaure M, Greten TF, Wang Z, Yu H, Wang XW. A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma. *Cell* 2020; **182**: 317-328.e10 [PMID: 32526205 DOI: 10.1016/j.cell.2020.05.038]

84 **Tanabe KK**, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. *JAMA* 2008; **299**: 53-60 [PMID: 18167406 DOI: 10.1001/jama.2007.65]

85 **Abu Dayyeh BK**, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. *Gastroenterology* 2011; **141**: 141-149 [PMID: 21440548 DOI: 10.1053/j.gastro.2011.03.045]

86 **Jiang G**, Yu K, Shao L, Yu X, Hu C, Qian P, Xie H, Li J, Zheng J, Zheng S. Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies. *BMC Cancer* 2015; **15**: 314 [PMID: 25927412 DOI: 10.1186/s12885-015-1318-6]

87 **Kumar V**, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011; **43**: 455-458 [PMID: 21499248 DOI: 10.1038/ng.809]

88 **Matsuura K**, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. *Gastroenterology* 2017; **152**: 1383-1394 [PMID: 28163062 DOI: 10.1053/j.gastro.2017.01.041]

89 **Hamdane N**, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. *Gastroenterology* 2019; **156**: 2313-2329.e7 [PMID: 30836093 DOI: 10.1053/j.gastro.2019.02.038]

90 **Calvaruso V**, Bruix J. Towards personalized screening for hepatocellular carcinoma: Still not there. *J Hepatol* 2020; **73**: 1319-1321 [PMID: 32771323 DOI: 10.1016/j.jhep.2020.06.032]

91 **Zhang H**, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. *Nat Genet* 2010; **42**: 755-758 [PMID: 20676096 DOI: 10.1038/ng.638]

92 **Jiang DK**, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. *Nat Genet* 2013; **45**: 72-75 [PMID: 23242368 DOI: 10.1038/ng.2483]

93 **Perumpail RB**, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. *Dig Dis Sci* 2015; **60**: 3142-3148 [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7]

94 **Demirtas CO**, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. *Eur J Gastroenterol Hepatol* 2020; **32**: 517-523 [PMID: 31524775 DOI: 10.1097/MEG.0000000000001528]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 11, 2021

**First decision:** April 18, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Filipec Kanizaj T **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Table 1** **Patients for whom surveillance of hepatocellular carcinoma is recommended according to society guidelines**

|  |
| --- |
| Cirrhotic patients regardless of etiology, Child-Pugh stage A-B[12-14] |
| Cirrhotic patients regardless of etiology, Child-Pugh stage C awaiting liver transplantation[12-14] |
| Asian male hepatitis B carriers over the age of 40 yr[12-14] |
| Asian female hepatitis B carriers over the age of 50 yr[12-14] |
| Hepatitis B carriers with a family history of HCC[12-14] |
| Non-cirrhotic F3 patients, regardless of etiology, may be considered for surveillance based on an individual risk assessment[14] |

HCC: Hepatocellular carcinoma.

**Table 2** **Hepatocellular carcinoma prediction risk scores for chronic hepatitis B patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Risk scores** | **Cohort: Patients/ratio of cirrhosis** | **Study population** | **Antiviral treatment** | **Variables** | **External validation** |
| GAG-HCC (Yuen *et al*[26], 2009) | Training: 820/15%  Validation: - | Asian (Hong Kong) | No | Age; Gender; HBV-DNA; Cirrhosis | Asian, Caucasian |
| CU-HCC (Wong *et al*[27], 2010) | Training: 1055/38%; Validation: 428/16% | Asian (Hong Kong) | No | Age; Albumin; Bilirubin; HBV-DNA; Radiologic cirrhosis | Asian, Caucasian |
| REACH-B (Yang *et al*[29], 2011) | Training: 3584/0; Validation: 1505/18% | Asian (Taiwan) | No | Age; Gender; ALT; HBeAg status; HBV-DNA concentration | Asian, Caucasian |
| REACH-BII  (Lee *et al*[30], 2013) | Training: 2227/0; Validation: 1113/0 | Asian (Taiwan) | No | Age; Gender; ALT; HBeAg/HBV-DNA/HBsAg/Genotype status | - (Internal only) |
| mREACH-B (Lee *et al*[31], 2014) | Training: 192/46.9%; Validation: - | Asian (South Korea) | ETV | Gender; ALT; HBeAg status; LSM value | Asian |
| LSM-HCC (Wong *et al*[33], 2014) | Training: 1035/32%; Validation: 520/31% | Asian (Hong Kong) | No | Age; Albumin; HBV-DNA concentration; LSM value | Asian |
| RWS-HCC (Poh *et al*[34], 2016) | Training: 583/13.7%; Validation: 3353/NA | Asian (Singapore) | No | Age; Sex; Cirrhosis; AFP | Asian, Caucasian |
| PAGE-B (Papatheodoridis *et al*[39], 2016) | Training: 1325/20%; Validation: 490/48% | Caucasians (Europe) | ETV/TDF | Age; Gender; Platelet count | Asian, Caucasian |
| mPAGE-B (Kim *et al*[42], 2018) | Training: 2001/19%; Validation: 1000/20% | Asian (South Korea) | ETV/TDF | Age; Gender; Platelet count; Albumin | Asian |
| HCC-RESCUE(Sohn *et al*[44], 2017) | Training: 990/39%; Validation: 1071/35% | Asian (South Korea) | ETV | Age; Gender; Cirrhosis | Asian |
| APA-B (Chen *et al*[45], 2017) | Training: 883/36%; Validation: 442/236% | Asian (Taiwan) | ETV | Age; Platelet; AFP | Asian |
| HCC-ESC (Fung *et al*[35], 2018) | Training: 723/NA; Validation: - | Asian (Hong Kong) | No | Age; Gender; Cirrhosis; Hypoalbuminemia; HBV-DNA; ALT | - |
| CAMD (Hsu *et al*[46], 2018) | Training: 23851/26.4%; Validation: 19321/7.1% | Asian (Taiwan) | ETV/TDF | Age; Gender; Diabetes; Cirrhosis | Asian |
| AGED (Fan *et al*[36], 2019) | Training: 628/0%; Validation: 1663/0% | Asian (China) | No | Age; Gender; HBeAg status; HBV-DNA | - (Internal only) |
| AASL-HCC (Yu *et al*[47], 2019) | Training: 944/39%; Validation: 298/39% | Asian (South Korea) | ETV/TDF | Age; Gender; Albumin; Cirrhosis | Asian |
| REAL-B (Yang *et al*[48], 2020) | Training: 5365/20.2%; Validation: 2683/22.1% | Asian (Multiethnicity) | Yes (not specified) | Age; Gender; Alcohol use; Diabetes; Platelet count; Cirrhosis; AFP | - (Internal only) |
| HCC-ESCAVT(Lim *et al*[49], 2020) | Training: 769/41.5%; Validation: 1061/26.1% | Asian (South Korea) | ETV/TDF | Gender; Cirrhosis; Fibrosis-4 index | - (Internal only) |

GAG-HCC: The guide with age, gender, hepatitis B virus DNA, core promoter mutations, and cirrhosis risk score; CU-HCC: Chinese University-hepatocellular carcinoma risk score; REACH-B: The risk estimation for hepatocellular carcinoma in chronic hepatitis B score; RWS: Real-world score; APA-B: Age, platelet, alpha-fetoprotein-B score; CAMD: Cirrhosis, age, male gender, diabetes score; AFP: Alpha-fetoprotein, ALT: Alanine aminotransferase, HBeAg: Hepatitis B e Antigen, HBV: Hepatitis B virus, LSM: Liver stiffness measurement.

**Table 3** **Hepatocellular carcinoma prediction risk scores for chronic hepatitis C patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Cohort: Patients/ratio of cirrhosis** | **Study population** | **Variables** | **External validation** |
| Lok *et al*[56], 2009 | Training: 1050/41%; Validation: - | North America (United States HALT-C cohort) | Age; Race (Black); ALP; Esophageal varices; Ever smoked; Platelet count | - |
| Masuzaki *et al*[58], 2009 | Training: 866/22.6%; Validation: - | Asian (Japan) | LSM | - |
| Chang *et al*[59], 2012 | Training: 871/27.9%; Validation: - | Asian (Taiwan) | Age; Platelet count; AFP; Fibrosis stage | - |
| El-Serag HB *et al*[57], 2014 | Training: 11721/100%; Validation: 52135/0 | North America (United States Veterans Administration) | Age; ALT; Platelet; AFP | - |
| Ganne-Carrié *et al*[60],2016 | Training: 720/100%; Validation: 360/100% | Caucasian (France) | Age; Past excessive alcohol intake; Platelet count; GGT; SVR status | - |
| Shiha *et al*[63], 2020 (GES) | Training: 2372/73.1%; Validation 1: 687/61.5%; Validation 2: 1314/70.6% | Egypt | Age; Gender; Fibrosis stage; Albumin; Alpha-feto protein | Egypt |

AFP: Alpha-fetoprotein, ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, GGT: Gamma-glutamyl transferase, LSM: Liver stiffness measurement, SVR: Sustained virologic response.

**Table 4 Hepatocellular carcinoma prediction risk scores regardless of etiology**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk scores** | **Cohort: Patients** | **Study population** | **Variables** | **External validation** |
| ADRESS-HCC, (Flemming *et al*[64], 2014) | Training: 17124/100%; Validation:17808/100% | North America (United States) | Age; Diabetes; Race; Etiology of liver disease; Gender; Child-Pugh Score | - (Internal only) |
| THRI, (Sharma *et al*[65], 2017) | Training: 2079/100%; Validation: 1144/100% | Caucasian (Canada) | Age; Gender; Etiology of liver disease; Platelet count | Asian, Caucasian |
| TDS, (Li *et al*[68], 2018) | Training: 21149/NA; Validation:10574/NA | Asian (Taiwan) | Age; Gender; Smoking status; HbA1c; Glutamic-pyruvic transaminase; Cirrhosis; Hepatitis B virus; Hepatitis C virus; Anti-diabetic medication; Anti-hyperlipidemic medicaiton; Total/HDL cholesterol ratio | - (Internal only) |
| aMAP, (Fan *et al*[69], 2020) | Training: 3688/19.3%; Validation cohorts: 13686/11.4%-100% | Multicenter (Asian + Caucasian) | Age; Gender; Albumin-bilirubin score; Platelet count | Asian, Caucasian |

THRI: Toronto hepatocellular carcinoma risk index; ADRESS: Age, diabetes, race, etiology of cirrhosis, sex, and severity; HbA1c: Hemoglobin A1c; HDL: High-density lipoprotein.

**Table 5 Algorithmic approaches using the combination of serologic and clinical parameters for hepatocellular carcinoma risk prediction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk scores** | **Cohort: Patients/ratio of cirrhosis** | **Study population** | **Variables** | **External validation** |
| GALAD score (Johnson *et al*[72], 2014) | HCC case: 670/90%; CLD control: 339/97% | Caucasian (England) | AFP; AFP-L3; DCP | Asian, Caucasian |
| Doylestown algorithm (Wang *et al*[76], 2016) | Training HCC case: 165/100%; CLD control: 195/100%; Validation 1 HCC case: 432/100%; CLD control: 438/100%; Validation 2 HCC case: 113/100%; CLD control: 586/100%; Validation 3 HCC case: 425/100%; CLD control: 804/100% | North America (United States) | Age; Gender; ALT; ALP; AFP; Fucosylated kininogen | North America (United States) |
| GALADUS score (Yang *et al*[75], 2019) | Training HCC case: 111/98%; CLD control: 180/85%; Validation HCC case: 233/100%; CLD control: 412/100% | North America (United States) | AFP; AFP-L3; DCP; Ultrasonography | North America (United States) |
| HES algorithm (Tayob *et al*[78,79], 2019) | HCC case: 4804/100%; CLD control: 33627/100% | North American (United States Veterans Administration) | Age; Rate of AFP change; ALT; Platelet count; Etiology of cirrhosis | - |

AFP: Alpha-fetoprotein; AFP-L3: Alpha-fetoprotein-L3; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; DCP: Des-gamma-carboxy-prothrombin, HCC: Hepatocellular carcinoma; CLD: Chronic liver disease.